Navigation Links
Micromet Key Events for 2009
Date:1/5/2009

tients with metastatic breast cancer. Micromet has licensed a fourth clinical stage antibody, MT293, to TRACON Pharmaceuticals, Inc. MT293 is being developed in a phase 1 clinical trial for the treatment of patients with cancer. The Company's preclinical programs include MT203, which is being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy and intended utilization of our product candidates and the development of our BiTE antibody technology. You are urged to consider statements that include the words "may," "potential," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, and th
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Expands Committed Equity Financing Facility to $75 Million
2. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
3. Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
4. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
5. Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results
6. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
7. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
8. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
9. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
10. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
11. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... FORT WORTH, Texas , Jan. 15, 2014  Humberto ... in Dermatology Achievement Award" from the Journal of ... Dermatology Aesthetic & Clinical Conference (ODAC). The event is January ... Florida . The ...
(Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very ... King as its new Chief Executive Officer.  Mark was ... which he has overseen the company,s four facilities in ... Costa Rica.  Mr. King joined Tegra Medical in 2012 with ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... Medical Corporation has provided an educational grant to establish ... .  "Atrium has been proud to be the market ... McGill, Senior Vice President of Marketing and Corporate Communications. ... nurses and physicians, we decided to emphasize our commitment ...
... 15, 2011 Johnson & Johnson (NYSE: ... agreement with Merck regarding distribution rights for REMICADE® (infliximab) ... The amended agreement announced today in a separate news ... had been filed by Johnson & Johnson in May ...
Cached Medicine Technology:Atrium Provides Grant to Establish Education Web Site at AtriumU.com 2Johnson & Johnson Provides Additional Information Regarding Amended Agreement With Merck 2Johnson & Johnson Provides Additional Information Regarding Amended Agreement With Merck 3
(Date:7/10/2014)... As the use of electronic health record becomes widespread ... implementation of the Affordable Care Act, the quantity of ... analytic purposes will also dramatically increase. Additionally, experts ... that analyze large quantities of data for the purpose ... the value of patient care a process that ...
(Date:7/10/2014)... (HealthDay News) -- Teens who are sensitive to light ... develop emotional symptoms such as anxiety and depression, a ... that may exacerbate issues teens experience after concussion may ... making decisions about when to return to play and ... study authors Lisa Koehl and Dong Han, of the ...
(Date:7/10/2014)... HealthDay Reporter THURSDAY, July 10, 2014 (HealthDay ... of calorie information on menus, if it,s available, to decide ... study. Women in particular review the menu labeling, said ... the U.S. Centers for Disease Control and Prevention. ... help choose their meal, compared with just under half of ...
(Date:7/10/2014)... captured with a microchip-based device developed at the Massachusetts ... the MGH Cancer Center can be cultured to establish ... In the July 11 issue of Science , ... accurately reflect a tumor,s genetic mutation over time and ... can culture cells from the blood that represent those ...
(Date:7/10/2014)... Human Services (HHS) has announced a three-year grant to ... totaling $4.7 million to support a new national model ... , Titled "Evidence-Conformant Oncology Care," the project will ... care for adult cancer patients with late-stage disease, significant ... , "We believe that the best cancer ...
Breaking Medicine News(10 mins):Health News:Six cases where big data can reduce healthcare costs 2Health News:Six cases where big data can reduce healthcare costs 3Health News:Six cases where big data can reduce healthcare costs 4Health News:Some Teens May Face Emotional Problems After Concussion 2Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 2Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 3Health News:Cultured CTCs reveal genetic profile, potential drug susceptibility of breast cancer cells 2Health News:Cultured CTCs reveal genetic profile, potential drug susceptibility of breast cancer cells 3Health News:UH Case Medical Center awarded $4.7 million grant from HHS 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 3
... expert says physicians have unique opportunity to help parents ... ... Washington, DC (Vocus) October 1, ... and their families understand the http://www.childrensnational.org/?utm_source=pressrelease&utm_medium=9_30&utm_campaign=driving_safety [importance of responsible ...
... recent headlines from Wall Street portend tougher times on the horizon, ... smart about their marketing. So says Helmut G. Flasch, of Flasch ... he has shown countless medical professionals how to expand their practices ... ...
... Reduce Claim Fraud and Costs by 30 Percent, ... Euronext: ILO, ISIN: FR0004042364) today announced that Swiss ... is using ILOG,JRules(R) to automate its medical claims ... has been able to reduce,unnecessary medical treatments, provide ...
... the Oct. 1 issue of the journal Sleep ... ideation and attempts, and the use of alcohol, cannabis and ... the presence of insomnia in adolescents increases the risk of ... of these problems. Results indicate that adolescents who had symptoms ...
... , A study conducted by researchers at Mayo Clinic ... enhanced response to the weight loss drug sibutramine, while ... no weight. , The findings are published in the ... , In this randomized, double-blind, placebo-controlled study, Mayo researchers ...
... simple questionnaire can reliably predict whether they will ... Hopkins researchers suggest in a new study. The ... benefit from additional preoperative preparation to ensure they ... exercise, a factor that can greatly affect their ...
Cached Medicine News:Health News:Healthcare Providers Can Help Reduce Teen Driving Deaths 2Health News:Healthcare Providers Can Help Reduce Teen Driving Deaths 3Health News:Medical Marketing Expert Offers Dentists Tips for Thriving Down Economy After the Wall Street Dilemma 2Health News:Medical Marketing Expert Offers Dentists Tips for Thriving Down Economy After the Wall Street Dilemma 3Health News:Swiss Medical Group Selects ILog JRules to Streamline Claims Processing 2Health News:Swiss Medical Group Selects ILog JRules to Streamline Claims Processing 3Health News:Adolescent insomnia linked to depression and substance abuse during adolescence and young adulthood 2Health News:Genes affect weight loss drug effectiveness 2Health News:Will patients stick to physical therapy? Questionnaire can help doctors predict 2Health News:Will patients stick to physical therapy? Questionnaire can help doctors predict 3
MDI will work with your facility to determine the best interim lab to fit your needs and your site....
... 300 ,Oblique 45, ,Type 330 ,Straight, ... by setting the illumination between lenses ... ideal for use in ophthalmology and ... conventional compact microscope can; an advanced ...
... same as the model SP-8800 with one big exception. ... This mode has its own fixation targets to allow ... allows you to select an area on the cornea ... to calculate averages of multiple readings in any one ...
... MedCath is the largest and most experienced ... networks in the United States. Mobile laboratories ... a daily basis, from one hospital to ... geographic area. Each mobile laboratory is fully ...
Medicine Products: